18 and older, any sex, with Kidney Disease, End-Stage. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Symptoms - Trajectory of ChangePrimary· Trajectories of up to 24 months from start of enrollment to study completion
Assessed using the symptoms/problems domain of the Kidney Disease Quality of Life 36-Item Short Form Survey (KDQOL-36). The Symptoms/Problems domain has 12 items, each representing a symptom or side effect of kidney disease based on the past 4 weeks with 5 response items ranging from "Not Bothered at all = 100" to "Extremely Bothered = 0". Min Score = 0; Max score = 100. Higher score indicates better health.
Group
Value
95% CI
Clinician Support and Education Around Use of PROs in Home Dialysis Clinic
77.2
± 14.2
Usual Care
76.2
± 15.1
Person-centred Care - Trajectory of ChangePrimary· Trajectories of up to 24 months from start of enrollment to study completion
Assessed using the Patient Assessment of Care for Chronic Conditions (PACIC-20), a patient-reported experience measure on satisfaction with care over the past 6 months. The PACIC-20 is a 20-item survey based on five subscales: (1) patient activation, (2) delivery system design and decision support, (3) goal setting and tailoring, (4) problem-solving and contextual counselling, and (5) follow-up and coordination. Each item is rated on a five-point scale (from "Almost never = 0" to "Almost always = 5") and the subscale and total scores are based on average scores across items. Min score = 0; Max
Group
Value
95% CI
Clinician Support and Education Around Use of PROs in Home Dialysis Clinic
3.4
± 1.1
Usual Care
3.5
± 1.0
Utilization of Health ServicesSecondary· From study enrollment until completion (up to 24 months)
Assessed using health services data (i.e. average number of hospital admissions, trips to the emergency room) determined through SPOR Platform and Alberta Health Services electronic health records. Higher numbers indicates worse outcomes.
Hospitalizations
Group
Value
95% CI
Clinician Support and Education Around Use of PROs in Home Dialysis Clinic
1.99
± 2.15
Usual Care
2.33
± 2.52
Emergency Room Visits
Group
Value
95% CI
Clinician Support and Education Around Use of PROs in Home Dialysis Clinic
5.72
± 7.28
Usual Care
4.53
± 5.58
Number of Participants Who Selected "1 - Excellent" on Satisfaction With CareSecondary· Up to 24 months from start of enrollment to study completion
Assessed using one item added to the end of the Patient Assessment of Care for Chronic Conditions 20 item questionnaire (PACIC-20) related to care received. This item is from the NHS Outpatient Survey (2011). (RateClin) related to care received on a Likert-type scale from Excellent = 1 to Very Poor = 6. Min = 1, max = 6. The number of patients who selected "1 - Excellent" was tabulated and compared between the two groups. The higher the number the more patients who felt the care provided to them was excellent.
Group
Value
95% CI
Clinician Support and Education Around Use of PROs in Home Dialysis Clinic
654
Usual Care
547
Mental Health - Trajectory of ChangeSecondary· Trajectories of up to 24 months from start of enrollment to study completion
Assessed using the SF-12 mental component summary (MCS) subscale in the Kidney Disease Quality of Life 36-item Short-Form Survey (KDQOL-36). The SF-12 uses 2 items (psychological distress and psychological well being) to measure the MCS score. The summary score is transformed using Canadian norm-based scoring. The scores ranged from 0 (worst health) to 100 (best health). The higher the score the better the mental health.
Group
Value
95% CI
Clinician Support and Education Around Use of PROs in Home Dialysis Clinic
50.9
± 8.4
Usual Care
51.0
± 8.3
Quality of Life - Trajectory of ChangeSecondary· Trajectories of up to 24 months from start of enrollment to study completion
Assessed using the Euro Quality of Life EQ-5D-5L. This assessment uses a descriptive system for health-related Quality of Life states in adults consisting of 5 dimensions; Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each dimension is scored between 1 = indicating no problem and 5 = indicating unable to/extreme problems. An EQ-5D summary index is derived by applying a formula (the Canadian standard value set) that attaches values (weights) to each of the levels in each dimension. Index min= 0.0 max = 1.0. The higher the index the better the quality of life/st
Group
Value
95% CI
Clinician Support and Education Around Use of PROs in Home Dialysis Clinic
0.772
± 0.182
Usual Care
0.745
± 0.196
Sponsor's own description
People living with end-stage kidney disease (ESKD) need dialysis or transplantation in order to stay alive. This illness and treatment significantly impact peoples' health, emotions, work and relationships. To promote person-centred care, healthcare professionals should be asking patients about what matters to them and using this feedback to plan and deliver care. Patient-reported outcome and experience questionnaires (jointly referred to as PROs) allow patients to provide information about their quality of life, symptoms and experiences with care. PROs are increasingly used to help healthcare professionals learn about what is important to patients and the impacts of illness or treatments from patients' point of view. Embedding feedback from patients into routine clinical practice is important in end-stage kidney disease because of the physical and quality of life challenges these patients face when living with kidney failure.
PROs provide vital and often missing information that the healthcare team can use to support patients. However, PROs administered via paper questionnaires have been perceived as cumbersome, difficult to integrate with other health information and do not provide immediate feedback.
In this research, home dialysis patients will have the opportunity to complete electronically administered PROs (ePROs) and healthcare professionals will receive education about how to use PRO information. The goal is to learn how to support healthcare professionals to routinely use this information to inform patient care, and see if this makes a difference in patients' symptoms, person-centred care, quality of life and satisfaction with care.
Learning what matters most to patients is essential for healthcare professionals to provide person-centred care. This research will address the gap in our understanding of how to best use patients' reports in healthcare. Findings of this research may ultimately improve the quality of healthcare for Canadians living with end-stage kidney disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT05341882 — Adaptation of Mindfulness Training to Treat Moral Injury in Veterans
· Phase 3
· completed
NCT02690116 — Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
· NA
· completed
Other recruiting trials for Kidney Disease, End-Stage
Currently open trials in the same condition.
NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease
· recruiting
NCT06801262 — TreaT-Assay: the New Frontier for the Diagnosis of Acute Rejection in Kidney Transplantation
· recruiting
NCT04665310 — Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
· Phase 4
· active not recruiting
Other University of Alberta trials
Trials by the same sponsor.
NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation
· NA
· not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD
· Phase 1, PHASE2
· not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation
· NA
· not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle
· EARLY_PHASE1
· not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 5 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03149328.